Gain Therapeutics, Inc. (GANX)
NASDAQ: GANX · Real-Time Price · USD
1.890
+0.060 (3.28%)
At close: Feb 19, 2026, 4:00 PM EST
1.871
-0.019 (-1.00%)
After-hours: Feb 19, 2026, 4:12 PM EST
Gain Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
25
Market Cap
72.69M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | 55.18K | -84.93K | -60.62% |
| Dec 31, 2022 | 140.11K | -24.89K | -15.08% |
| Dec 31, 2021 | 164.99K | 136.11K | 471.29% |
| Dec 31, 2020 | 28.88K | -12.42K | -30.07% |
| Dec 31, 2019 | 41.30K | 20.69K | 100.40% |
| Dec 31, 2018 | 20.61K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| NovaBay Pharmaceuticals | 10.30M |
| ImageneBio | 800.00K |
| Coeptis Therapeutics Holdings | 501.00K |
| Mereo BioPharma Group | 500.00K |
| Seres Therapeutics | 351.00K |
| Entera Bio | 124.00K |
GANX News
- 6 weeks ago - Gain Therapeutics Announces Announces Conference Participation During J.P. Morgan Healthcare Conference Week - GlobeNewsWire
- 6 weeks ago - Gain Therapeutics Highlights Biomarker Evidence Supporting Disease-Modifying Potential of GT-02287 - GlobeNewsWire
- 2 months ago - Gain Therapeutics to Host Virtual KOL Event on GT-02287 for Parkinson's Disease - GlobeNewsWire
- 2 months ago - Gain Therapeutics Announces Positive Results in Key Exploratory Endpoint from its Phase 1b Clinical Study of GT-02287 in People with Parkinson's Disease - GlobeNewsWire
- 3 months ago - Gain Therapeutics Presents Preclinical GT-02287 Data at Neuroscience 2025 - GlobeNewsWire
- 3 months ago - Gain Therapeutics Reports Financial Results for Third Quarter 2025 and Provides Corporate Update - GlobeNewsWire
- 3 months ago - Gain Therapeutics: Valuation Remains Low In Light Of Recently Reported Functional Improvement In PD Patients - Seeking Alpha
- 4 months ago - Gain Therapeutics to Present at Neuroscience 2025 - GlobeNewsWire